What are the relevant information and characteristics of the Lao version of Avonib?

Lao version of Ivosidenib/Ivosidenib (Ivosidenib) is a generic IDH1 inhibitor produced by a local pharmaceutical company in Laos. It is mainly used to treat specific types of cancer, especially in patients with IDH1 gene mutations, showing significant efficacy. The original drug ivonib was originally developed by Agios Pharmaceuticals and has been approved by the FDA for IDH1-mutated acute myeloid leukemia (AML) and locally advanced or metastatic cholangiocarcinoma. The Lao version is mainly produced by companies such as Laos United Pharmaceuticals, Daxiong Pharmaceuticals, Lucius Pharmaceuticals and other companies, which greatly reduces the economic burden of the drug on the basis of ensuring that the active ingredients and treatment mechanisms are consistent.

The active ingredients of the Lao version of ivonib are consistent with the original research, and they are both inhibitors targeting isocitrate dehydrogenase-1 (IDH1) mutations. This drug restores the normal differentiation function of bone marrow cells by blocking the overproduction of 2-hydroxyglutarate (2-HG) caused by IDH1 mutations. It is especially suitable for AML patients whose differentiation is blocked due to IDH1 mutations. In addition, the drug is also suitable for some patients with cholangiocarcinoma. Such patients often have tumor cell metabolism disorders due to IDH1 mutations, thus forming a drug resistance mechanism. Through precise intervention at the molecular level, ivonib is expected to delay disease progression and improve treatment response rates.

In terms of specifications, the Lao version of Avosidenib is generally packaged in 250 mg/tablet and 60 tablets per bottle. It follows internationally accepted dosage standards and is convenient for daily maintenance treatment. The design of this dosage form is consistent with the original drug, ensuring the stability of drug release and controllability of blood drug concentration. In terms of cost, the Lao version of Avosidenib does not involve the original research patent premium and international distribution costs, so the price is relatively low, generally just over 3,000 yuan per bottle.

Reference: https://www.tibsovo.com/